» Articles » PMID: 24504172

Collagen Triple Helix Repeat Containing 1 (CTHRC1) Acts Via ERK-dependent Induction of MMP9 to Promote Invasion of Colorectal Cancer Cells

Overview
Journal Oncotarget
Specialty Oncology
Date 2014 Feb 8
PMID 24504172
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Collagen triple helix repeat-containing 1 (CTHRC1) is known to be aberrantly upregulated in most human solid tumors, although the functional roles of CTHRC1 in colorectal cancer remain unclear. In this study, we investigated the occurrence of CTHRC1 upregulation and its role in vivo and in vitro. The expression profile and clinical importance of CTHRC1 were examined by reverse transcription-polymerase chain reaction and immunohistochemical analyses in normal and tumor patient samples. CTHRC1 was detectable in normal tissues, but also was highly expressed in tumor specimens. CTHRC1 upregulation was significantly associated with demethylation of the CTHRC1 promoter in colon cancer cell lines and tumor tissues. Clinicopathologic analyses showed that nodal status and expression of CTHRC1 (95% CI 0.999-3.984, p=0.05) were significant prognostic factors for disease-free survival. Promoter CpG methylation and hypermethylation status were measured by bisulfite sequencing and pyrosequencing analysis. Furthermore, we showed that overexpression of CTHRC1 in the SW480 and HT-29 cell lines increased invasiveness, an effect mediated by extracellular signal-regulated kinase (ERK)-dependent upregulation of matrix metalloproteinase 9 (MMP9). Consistent with this, we found that knockdown of CTHRC1 attenuated ERK activation and cancer cell invasivity. These results demonstrate that CTHRC1 expression is elevated in human colon cancer cell lines and clinical specimens, and promotes cancer cell invasivity through ERK-dependent induction of MMP9 expression. Our results further suggest that high levels of CTHRC1 expression are associated with poor clinical outcomes.

Citing Articles

CTHRC1 expresses in cancer-associated fibroblasts and is associated with resistance to anti-androgen therapy in prostate cancer.

Liang H, He Q, Wei Q, Mo Q, Yang G, Wei F Genes Genomics. 2025; .

PMID: 40009323 DOI: 10.1007/s13258-025-01624-z.


The role of collagen triple helix repeat containing 1 (CTHRC1) in cancer development and progression.

Singh C, Fernandez S, Chhabra G, Zaemisch G, Nihal A, Swanlund J Expert Opin Ther Targets. 2024; 28(5):419-435.

PMID: 38686865 PMC: 11189736. DOI: 10.1080/14728222.2024.2349686.


CTHRC1 is a Potential Prognostic Biomarker and Correlated with Macrophage Infiltration in Breast Cancer.

Wang Z, Zhang S, Zheng C, Xia K, Sun L, Tang X Int J Gen Med. 2022; 15:5701-5713.

PMID: 35755862 PMC: 9231633. DOI: 10.2147/IJGM.S366272.


The Inhibition of Gastric Cancer Cells' Progression by 23,24-Dihydrocucurbitacin E through Disruption of the Ras/Raf/ERK/MMP9 Signaling Pathway.

Liu H, Wang H, Dong A, Huo X, Wang H, Wang J Molecules. 2022; 27(9).

PMID: 35566048 PMC: 9100127. DOI: 10.3390/molecules27092697.


CTHRC1 targeted by miR-30a-5p regulates cell adhesion, invasion and migration in lung adenocarcinoma.

Yang C, Huang T, Liang Y, Xue Y, Liang Y, Wei X J Cardiothorac Surg. 2022; 17(1):46.

PMID: 35313900 PMC: 8935819. DOI: 10.1186/s13019-022-01788-9.


References
1.
Wong J, Chan S, Schaeffer D, Sagaert X, Lim H, Kennecke H . Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer. Clin Cancer Res. 2011; 17(12):4167-76. DOI: 10.1158/1078-0432.CCR-10-1224. View

2.
Li J, Cao J, Li M, Yu Y, Yang Y, Xiao X . Collagen triple helix repeat containing-1 inhibits transforming growth factor-b1-induced collagen type I expression in keloid. Br J Dermatol. 2011; 164(5):1030-6. DOI: 10.1111/j.1365-2133.2011.10215.x. View

3.
Burg-Roderfeld M, Roderfeld M, Wagner S, Henkel C, Grotzinger J, Roeb E . MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int J Oncol. 2007; 30(4):985-92. DOI: 10.3892/ijo.30.4.985. View

4.
Kim J, Song E, Chung K, Kang M, Kim J, Kim S . Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer. Cancer. 2011; 117(12):2608-19. DOI: 10.1002/cncr.25841. View

5.
Yamamoto S, Nishimura O, Misaki K, Nishita M, Minami Y, Yonemura S . Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell. 2008; 15(1):23-36. DOI: 10.1016/j.devcel.2008.05.007. View